Zydus Lifesciences gets US FDA approval for generic diabetes drug
Zydus Lifesciences on Wednesday has received approval from the US health regulator to market a generic diabetes drug in the US market.
Zydus Lifesciences on Wednesday has received approval from the US health regulator to market a generic diabetes drug in the US market.
The company has received tentative approval from the US Food and Drug Administration (USFDA) for Dapagliflozin Tablets in strengths of 5 mg and 10 mg, the drug firm said in a statement.
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.
The company said the tablets will be manufactured at its formulation manufacturing facility at SEZ, Ahmedabad. As per the industry estimates, Dapagliflozin tablets had annual sales of USD 10,486.9 million in the US.
More from BusinessZydus shares on Wednesday ended 0.23 per cent up at Rs 905 apiece on BSE.
(Except for the headline, this story has not been edited by Firstpost staff.)
US jobless claims fall to 187,000, signalling resilient labour market ahead of Fed meeting
NDTA asks Connaught Place shops, offices and restaurants to close by 6:30 pm today
EU slaps Google with $1 billion antitrust fine over Play Store and Search practices
Brent crude flirts with $100, reigniting inflation and forex concerns for India
Can a record May offset a shrunk international schedule and help IndiGo turn a profit?